Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder
Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
The specific aim of this trial is to determine if hydrodistention at the time of
intradetrusor injection of botulinum toxin A has additional benefit in patients with
refractory overactive bladder (OAB) and urgency symptoms compared to intradetrusor injection
of botulinum toxin A alone.
Consented patients will be randomized to hydrodistention at a pressure of 80 cm H2O for 5
minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
(hydrodistention group) or intradetrusor injection of 100 units of botulinum toxin A alone
(botulinum toxin A alone group).
The primary aim will be subjective improvement measured as change from baseline at 12 weeks
using the OAB-q bother subscale.
Phase:
N/A
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A